November 25, 2016 - By Louis Casey · 0 Comments
The stock of Axogen Incorporated (NASDAQ:AXGN) registered an increase of 16% in short interest. AXGN’s total short interest was 1.28 million shares in November as published by FINRA. Its up 16% from 1.10 million shares, reported previously. With 133,400 shares average volume, it will take short sellers 10 days to cover their AXGN’s short positions. The short interest to Axogen Incorporated’s float is 6.15%. The stock increased 1.16% or $0.1 on November 23, hitting $8.75. AxoGen, Inc. (NASDAQ:AXGN) has risen 59.09% since April 22, 2016 and is uptrending. It has outperformed by 53.68% the S&P500.
Out of 3 analysts covering AxoGen (NASDAQ:AXGN), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. AxoGen has been the topic of 7 analyst reports since August 11, 2015 according to StockzIntelligence Inc. As per Monday, November 7, the company rating was maintained by Wedbush. The stock of AxoGen, Inc. (NASDAQ:AXGN) has “Hold” rating given on Thursday, November 3 by Lake Street. Lake Street upgraded it to “Buy” rating and $11 target price in Tuesday, November 22 report. The stock has “Outperform” rating given by Wedbush on Friday, August 28. Zacks upgraded the stock to “Hold” rating in Tuesday, August 11 report.
AxoGen, Inc. (AxoGen), incorporated on June 20, 1977, is a medical technology firm focused on peripheral nerve repair. The Firm provides products and education to improve surgical treatment algorithms for peripheral nerve injuries. The Company’s regenerative medicine products include Avance Nerve Graft, a processed nerve allograft for bridging severed nerves without the comorbidities associated with a nerve autograft additional surgical site; AxoGuard Nerve Connector, a porcine submucosa ExtraCellular Matrix (ECM) coaptation aid for repair of severed nerves, and AxoGuard Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves. The Firm also sells AxoTouch Two Point Discriminator, a measurement tool for determining innervation density and sensory function.
More notable recent AxoGen, Inc. (NASDAQ:AXGN) news were published by: Globenewswire.com which released: “AxoGen, Inc. Announces Commercial Release and First Clinical Implant of Avive …” on November 21, 2016, also Globenewswire.com with their article: “AxoGen, Inc. Announces the Refinancing of its Debt Facility” published on October 26, 2016, Globenewswire.com published: “AxoGen, Inc. to Host Analyst and Investor Event on November 21, 2016” on November 15, 2016. More interesting news about AxoGen, Inc. (NASDAQ:AXGN) were released by: Globenewswire.com and their article: “AxoGen, Inc. Reports Financial Results for Third Quarter 2016” published on November 02, 2016 as well as Quotes.Wsj.com‘s news article titled: “News AxoGen Inc.AXGN” with publication date: May 17, 2012.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Louis Casey